Information:
Fel:
ID
34177
Beskrivning
Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers; ODM derived from: https://clinicaltrials.gov/show/NCT02098954
Länk
https://clinicaltrials.gov/show/NCT02098954
Nyckelord
Versioner (1)
- 2019-01-15 2019-01-15 -
Rättsinnehavare
GSK group of companies
Uppladdad den
15 januari 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Carcinoma, Non-Small Cell Lung NCT02098954
Eligibility Carcinoma, Non-Small Cell Lung NCT02098954
- StudyEvent: Eligibility
Similar models
Eligibility Carcinoma, Non-Small Cell Lung NCT02098954
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
ID.1
Item
advanced non-small cell lung cancer, stage iiib/iv
boolean
ID.2
Item
non-squamous
boolean
ID.3
Item
egfr sensitive mutations, such as exon 19 del, or exon 21 l858r
boolean
ID.4
Item
received first line tkis treatment and developed tki resistance
boolean
ID.5
Item
ecog 0-2
boolean
ID.6
Item
squamous non-small cell lung cancer
boolean
ID.7
Item
patients have unstable brain metastasis, predict survival less than 8 weeks
boolean
ID.8
Item
spinal-cord compression without evidence of stabilisation or treatment
boolean
ID.9
Item
women who were pregnant or lactating; women with a positive or no available pregnancy test result at baseline
boolean
ID.10
Item
patients have any unstable illness that could not receive further treatment
boolean